NASDAQ:INMB | Free Cash Flow | Inmune Bio, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2017-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$3.4M
2025-12-31-$2.94M$143,000.00-$3.09M
2025-03-31-$6.82M
2024-12-31-$11.01M
2024-03-31-$7.48M
2023-12-31-$3.4M
2023-03-31-$1.14M
2022-12-31-$5.7M
2022-03-31-$8.87M
2021-12-31-$9.78M
2021-03-31-$5.09M
2020-12-31-$2.39M
2020-03-31-$1.04M
2019-12-31-$433,370.00
2019-03-31-$1.39M
2018-12-31-$462,377.00
2018-03-31-$328,841.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$22.58M$1.04M-$23.62M
2024-12-31-$33.36M
2023-12-31-$11.98M
2022-12-31-$22.69M
2021-12-31-$28.5M
2020-12-31-$8.94M
2019-12-31-$5.38M
2018-12-31-$2.06M
2017-12-31-$761,834.00